See more : Sumitomo Pharma Co., Ltd. (4506.T) Income Statement Analysis – Financial Results
Complete financial analysis of MustGrow Biologics Corp. (MGROF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MustGrow Biologics Corp., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
You may be interested
- FIH Mobile Limited (2038.HK) Income Statement Analysis – Financial Results
- Menon Pistons Limited (MENNPIS.BO) Income Statement Analysis – Financial Results
- Celularity Inc. (CELU) Income Statement Analysis – Financial Results
- Poste Italiane S.p.A. (PST.MI) Income Statement Analysis – Financial Results
- Kahan Packaging Limited (KAHAN.BO) Income Statement Analysis – Financial Results
MustGrow Biologics Corp. (MGROF)
About MustGrow Biologics Corp.
MustGrow Biologics Corp., an agricultural biotech company, focuses om development and commercialization of natural biopesticide, biofumigants, and bioherbicides derived from mustard seed. It provides preplant soil biofumigation, a technology to treat soil-borne diseases and pests for various crops, including fruit, vegetables, and other crops. The company is also developing bioherbicide to treat unwanted plant growth for use in organic agriculture, home, and garden markets, as well as agriculture markets; and postharvest food preservation, an application in sprout, disease, and pathogen treatment for storage and food preservation markets. In addition, it focuses on providing CannaPM, an active ingredient to treat fungal soil diseases, as well as foliar diseases. The company was formerly known as Duport Capital Ltd. and changed its name to MustGrow Biologics Corp. in March 2018. MustGrow Biologics Corp. was incorporated in 2014 and is headquartered in Saskatoon, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.71M | 6.48K | 12.87K | 0.00 | 0.00 | 2.00K | 2.10K | 109.02K | 12.42K |
| Cost of Revenue | 384.69K | 298.21K | 203.59K | 187.68K | 74.19K | 44.74K | 48.71K | 21.26K | 75.80K |
| Gross Profit | 4.33M | -291.73K | -190.72K | -187.68K | -74.19K | -42.74K | -46.60K | 87.76K | -63.38K |
| Gross Profit Ratio | 91.84% | -4,502.72% | -1,482.03% | 0.00% | 0.00% | -2,136.90% | -2,217.13% | 80.50% | -510.45% |
| Research & Development | 857.07K | 475.86K | 458.38K | 149.25K | 83.00K | 13.54K | 749.00 | 21.26K | 75.80K |
| General & Administrative | 3.12M | 4.52M | 2.00M | 2.96M | 1.35M | 1.84M | 36.45K | 20.44K | 491.92K |
| Selling & Marketing | 558.60K | 696.82K | 567.93K | 263.55K | 36.47K | 9.49K | 0.00 | 0.00 | 0.00 |
| SG&A | 3.68M | 5.22M | 2.57M | 3.22M | 1.39M | 1.84M | 36.45K | 20.44K | 491.92K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.54M | 5.69M | 3.02M | 3.37M | 1.47M | 1.86M | 36.45K | 20.44K | 519.35K |
| Cost & Expenses | 4.92M | 5.69M | 3.02M | 3.37M | 1.47M | 1.86M | 36.45K | 20.44K | 595.15K |
| Interest Income | 211.60K | 103.55K | 3.32K | 45.87K | 45.88K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 10.07K | 52.77K | 45.87K | 45.88K | 40.24K | 27.31K | 0.00 | 0.00 |
| Depreciation & Amortization | -466.01K | 5.25M | 2.73M | 3.20M | 1.35M | 892.64K | 1.08K | 1.08K | 2.31K |
| EBITDA | -676.94K | 0.00 | 0.00 | 0.00 | 0.00 | -1.85M | -170.25K | -147.89K | -555.31K |
| EBITDA Ratio | -14.37% | -86,148.73% | -23,398.17% | 0.00% | 0.00% | -92,656.85% | -1,734.11% | -18.75% | -4,472.14% |
| Operating Income | -210.93K | -5.58M | -3.01M | -3.37M | -1.47M | -1.85M | -36.45K | -20.44K | -557.62K |
| Operating Income Ratio | -4.48% | -86,148.73% | -23,398.17% | 0.00% | 0.00% | -92,656.85% | -1,734.11% | -18.75% | -4,490.77% |
| Total Other Income/Expenses | -466.01K | -313.51K | -334.69K | -109.90K | -164.09K | -40.24K | 250.74K | 108.35K | -25.12K |
| Income Before Tax | -676.94K | -5.57M | -3.06M | -3.31M | -1.52M | -1.89M | -36.45K | -20.44K | -582.73K |
| Income Before Tax Ratio | -14.37% | -85,905.87% | -23,808.18% | 0.00% | 0.00% | -94,668.85% | -1,734.11% | -18.75% | -4,693.03% |
| Income Tax Expense | 0.00 | -5.24M | -2.73M | -3.15M | -1.35M | -161.14K | 88.55K | -24.40K | 0.00 |
| Net Income | -676.94K | -5.57M | -3.06M | -3.31M | -1.52M | -1.89M | -36.45K | -20.44K | -582.73K |
| Net Income Ratio | -14.37% | -85,905.87% | -23,808.18% | 0.00% | 0.00% | -94,668.85% | -1,734.11% | -18.75% | -4,693.03% |
| EPS | -0.01 | -0.11 | -0.07 | -0.09 | -0.06 | -0.08 | 0.00 | 0.00 | -0.03 |
| EPS Diluted | -0.01 | -0.11 | -0.07 | -0.09 | -0.06 | -0.08 | 0.00 | 0.00 | -0.03 |
| Weighted Avg Shares Out | 49.90M | 49.01M | 43.74M | 37.31M | 25.29M | 24.99M | 24.99M | 24.99M | 20.91M |
| Weighted Avg Shares Out (Dil) | 49.89M | 49.01M | 43.74M | 37.31M | 25.29M | 24.99M | 24.99M | 24.99M | 20.91M |
MustGrow Biologics Upsizes Private Placement to $6.9 Million; Gluskin Invests $1 Million
Saskatoon, Saskatchewan--(Newsfile Corp. - September 29, 2021) - MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FSE: 0C0) ("MustGrow") is pleased to announce it has upsized its previously-announced C$2.0 million non-brokered private placement (the "Private Placement") to approximately 2.7 million units...
MustGrow Biologics Arranges $2 Million Equity Private Placement
Saskatoon, Saskatchewan--(Newsfile Corp. - September 13, 2021) - MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) ("MustGrow") is pleased to announce a non-brokered private placement (the "Private Placement") of approximately 770,000 units (each a "Unit") for gross proceeds of...
MustGrow Biologics Announces Positive Carnation Trials with Gowan
Work completed under non-exclusive agreement with Gowan Group's biological division Ecoflora Agro in Colombia.MustGrow and Gowan reported control of Fusarium disease in carnation flower soil utilizing MustGrow's mustard-derived biopesticide.Soil treated with MustGrow's product showed resilient carnation yield and health, suggesting...
MustGrow Achieves Control of Root-Rot Disease Aphanomyces in Greenhouse Trials
Disease control of root-rot Aphanomyces in greenhouse testing across a range of economic rates.Plants treated with MustGrow's biopesticide were robust in plant and root system health.Aphanomyces is a soil-borne root-rot disease that destroys pulse crops (peas, lentils, and legumes).90% of...
MustGrow Investor Webcast Today - Tuesday May 4th at 4:10pm ET
Saskatoon, Saskatchewan--(Newsfile Corp. - May 4, 2021) - MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FSE: 0C0) (the "Company", "MustGrow"), an agriculture technology company focused on providing natural biological crop protection solutions, will discuss (via live webcast) recent achievements and...
MustGrow Biologics and Univar Canada Ltd. Subsidiary NexusBioAg Announce Collaborative Field Trials Program in Canada
Field Trials to commence for MustGrow's mustard-derived soil biopesticide in Canada for treatment of Clubroot disease in Canola and Aphanomyces disease in Pulse Crops. MustGrow's organic biopesticide is plant-based, harnessing the mustard seed's natural defense mechanism to control diseases, insect...
MustGrow Highlights Positive Soil Health and Environmental Approach; Earth Day Investor Presentations
[DATELINE]MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FSE: 0C0) (the "Company", "MustGrow") is pleased to outline its environmentally-sustainable approach to crop protection on Earth Day. MustGrow's safe and effective natural, organic biofumigant, biopesticide and bioherbicide are plant-based - harnessing the...
MustGrow Outlines Upcoming Investment Conferences
Saskatoon, Saskatchewan--(Newsfile Corp. - April 15, 2021) - MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FSE: 0C0) (the "Company", "MustGrow") is pleased to announce its upcoming investor awareness initiatives. MustGrow continues to actively engage its key stakeholders - potential industry...
MustGrow Biologics Reports Positive Tobacco Field Trial Results Versus Synthetic Chemical "Chloropicrin"
Comparable efficacy and yield results with MustGrow's natural mustard-derived biological products versus Chloropicrin.Field study funded via collaboration with a 3rd party research organization.MustGrow's organic biopesticide is plant-based, harnessing the mustard seed's natural defense mechanism to control diseases, insect pests and...
MustGrow Isolates and Concentrates a Mustard-Derived Molecule that Acts as a Systemic, Non-Selective Bioherbicide
MustGrow has isolated and concentrated a new mustard-derived extract, thiocyanate.Thiocyanate is soil active and translocated in the plant as a systemic, non-selective bioherbicide (natural weed-killer). Greenhouse weed treatment studies have commenced with this new bioherbicide extract.Saskatoon, Saskatchewan--(Newsfile Corp. - March...
Source: https://incomestatements.info
Category: Stock Reports